Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Branford

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatmentAndrew M Stein, Dean Bottino, Vijay Modur, et al.
Transplantation and Cellular Therapy|January 22, 2026
Long-term survival gains after allogeneic hematopoietic stem cell transplant are driven by reductions in non-relapse mortality: A 35-Year Statewide Australian cohort studyAlia Cibich, Gauri Wechalekar, Naranie Shanmuganathan, et al.
Journal of Clinical Pathology|February 4, 2016
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemiaSusan Latham, Paul A Bartley, Bradley Budgen, et al.
The Journal of Molecular Diagnostics : JMD|January 3, 2015
A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemiaPaul A Bartley, Susan Latham, Bradley Budgen, et al.
Bioinformatics (Oxford, England)|July 12, 2013
A comparative analysis of algorithms for somatic SNV detection in cancerNicola D Roberts, R Daniel Kortschak, Wendy T Parker, et al.
Blood|April 11, 2019
Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionNaranie Shanmuganathan, Jodi A Braley, Agnes S M Yong, et al.
Blood Neoplasia|June 2, 2025
CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinibChung Hoow Kok, Yazad Irani, Jade Clarson, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
British Journal of Haematology|May 27, 2022
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remissionLiu Lu, Chung Hoow Kok, Phuong Dang, et al.
Blood Advances|January 9, 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemiaYazad D Irani, Chung H Kok, Jade Clarson, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatmentAndrew M Stein, Dean Bottino, Vijay Modur, et al.
Transplantation and Cellular Therapy|January 22, 2026
Long-term survival gains after allogeneic hematopoietic stem cell transplant are driven by reductions in non-relapse mortality: A 35-Year Statewide Australian cohort studyAlia Cibich, Gauri Wechalekar, Naranie Shanmuganathan, et al.
Journal of Clinical Pathology|February 4, 2016
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemiaSusan Latham, Paul A Bartley, Bradley Budgen, et al.
The Journal of Molecular Diagnostics : JMD|January 3, 2015
A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemiaPaul A Bartley, Susan Latham, Bradley Budgen, et al.
Bioinformatics (Oxford, England)|July 12, 2013
A comparative analysis of algorithms for somatic SNV detection in cancerNicola D Roberts, R Daniel Kortschak, Wendy T Parker, et al.
Blood|April 11, 2019
Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionNaranie Shanmuganathan, Jodi A Braley, Agnes S M Yong, et al.
Blood Neoplasia|June 2, 2025
CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinibChung Hoow Kok, Yazad Irani, Jade Clarson, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
British Journal of Haematology|May 27, 2022
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remissionLiu Lu, Chung Hoow Kok, Phuong Dang, et al.
Blood Advances|January 9, 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemiaYazad D Irani, Chung H Kok, Jade Clarson, et al.
Pageof 14